BA-101
/ Beyond Air
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
July 01, 2026
Targeting Temozolomide-Resistant Glioblastoma: Therapeutic Potential of Neuronal Nitric Oxide Synthase Inhibitor.
(PubMed, Cancer Med)
- "Collectively, our findings strongly suggest that BA-101 has potential for further preclinical and translational development as an anticancer agent and a novel TMZ chemosensitizer for GBM therapy."
Journal • Brain Cancer • Glioblastoma • Oncology • Solid Tumor • ANXA5
September 08, 2025
NeuroNOS Granted FDA Orphan Drug Designation for Glioblastoma, the Most Common and Deadliest Primary Malignant Brain Cancer in Adults
(GlobeNewswire)
Orphan drug • Glioblastoma
1 to 2
Of
2
Go to page
1